Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Carcinoma, Hepatocellular 4Esophageal Neoplasms 3Nasopharyngeal Carcinoma 2Immunotherapy 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2SCLC, Extensive Stage 1Mid-low Rectal Cancer 1Melanoma 1Locally Advanced Rectal Cancer 1Laryngeal Neoplasms 1Immunotherapy Gastrict Cancer 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Advanced Non-small-cell Lung Cancer 1

Interventions

tislelizumab 2Oxaliplatin 2apatinib 1Tegafur 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Immunotherapy × tislelizumab × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting
94 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡